An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma

Trial Profile

An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs MDNA 55 (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors Medicenna Therapeutics
  • Most Recent Events

    • 10 Oct 2017 According to a Medicenna Therapeutics media release, data were presented at the 2017 Congress of Neurological Surgeons.
    • 28 Sep 2017 According to a Medicenna Therapeutics media release, safety and pharmacokinetic date will be presented at the Congress of Neurological Surgeons conference 2017 in Boston.
    • 28 Sep 2017 Based on a planned safety analysis following a unanimous recommendation from MDNA55's Safety Review Committee (SRC), after enrollment of the first six patients, Medicenna has implemented the updated protocol following its submission to the USFDA and approval by the Institutional Review Boards (IRBs). The amended protocol includes an enhanced drug delivery procedure, dose doubled to 3.0mg/mL and administered as a maximized volume of 60mL, planned patient number changed from 43 to 52.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top